Amarin drama, ahead of the drama
In just nine short days, an FDA advisory committee will meet to assess the clinical evidence in support of Vascepa, the closely watched fish-oil-derived heart drug from Amarin. But the pre-show drama is underway.
As STAT's Matthew Herper notes, a brief suggestion by Jefferies analyst Michael Yee — offered on a podcast — that Cleveland Clinic cardiologist Steven Nissen was in "correspondence with the FDA" over Vascepa sent certain members of bio-Twitter into a tailspin. Nissen, of course, is famous for having been outspoken about the cardiovascular risks of Merck’s Vioxx — and he's previously made no secret of his skepticism on Vascepa.
But Nissen told STAT said there's no there there. "There’s been no conversation that anybody could ever interpret under any circumstances as representing a discussion about Vascepa, end of story, period,” he said.
Read more.
As STAT's Matthew Herper notes, a brief suggestion by Jefferies analyst Michael Yee — offered on a podcast — that Cleveland Clinic cardiologist Steven Nissen was in "correspondence with the FDA" over Vascepa sent certain members of bio-Twitter into a tailspin. Nissen, of course, is famous for having been outspoken about the cardiovascular risks of Merck’s Vioxx — and he's previously made no secret of his skepticism on Vascepa.
But Nissen told STAT said there's no there there. "There’s been no conversation that anybody could ever interpret under any circumstances as representing a discussion about Vascepa, end of story, period,” he said.
Read more.
.png)
No hay comentarios:
Publicar un comentario